- Home
- JANX vs PZZA Comparison
JANX vs PZZA Comparison
Compare JANX & PZZA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- PZZA
- Stock Information
- Founded
- JANX 2017
- PZZA 1984
- Country
- JANX United States
- PZZA United States
- Employees
- JANX N/A
- PZZA N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- PZZA Restaurants
- Sector
- JANX Health Care
- PZZA Consumer Discretionary
- Exchange
- JANX Nasdaq
- PZZA Nasdaq
- Market Cap
- JANX 1.4B
- PZZA 1.4B
- IPO Year
- JANX 2021
- PZZA 1993
- Fundamental
- Price
- JANX $23.98
- PZZA $48.24
- Analyst Decision
- JANX Strong Buy
- PZZA Buy
- Analyst Count
- JANX 9
- PZZA 10
- Target Price
- JANX $85.00
- PZZA $52.33
- AVG Volume (30 Days)
- JANX 745.4K
- PZZA 1.1M
- Earning Date
- JANX 08-07-2025
- PZZA 08-07-2025
- Dividend Yield
- JANX N/A
- PZZA 3.83%
- EPS Growth
- JANX N/A
- PZZA 8.47
- EPS
- JANX N/A
- PZZA 2.28
- Revenue
- JANX $439,000.00
- PZZA $2,085,052,000.00
- Revenue This Year
- JANX N/A
- PZZA $4.40
- Revenue Next Year
- JANX $591.60
- PZZA $0.98
- P/E Ratio
- JANX N/A
- PZZA $21.10
- Revenue Growth
- JANX N/A
- PZZA N/A
- 52 Week Low
- JANX $21.97
- PZZA $30.16
- 52 Week High
- JANX $71.71
- PZZA $60.75
- Technical
- Relative Strength Index (RSI)
- JANX 49.92
- PZZA 57.24
- Support Level
- JANX $22.41
- PZZA $46.10
- Resistance Level
- JANX $24.00
- PZZA $48.57
- Average True Range (ATR)
- JANX 1.10
- PZZA 1.73
- MACD
- JANX 0.01
- PZZA 0.13
- Stochastic Oscillator
- JANX 42.20
- PZZA 72.03
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About PZZA Papa John's International Inc.
Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 6,000 restaurants across nearly 50 countries at the end of 2024. The firm operates a predominantly franchised system, owning 9% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain globally and third in the US (Euromonitor International), with a sizable presence in the UK, China, South Korea, and Chile.